Decreased Expression of miR-548c-3p in Osteosarcoma Contributes to Cell Proliferation Via Targeting ITGAV

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Integrin αv (ITGAV) family members are implicated in tumor progression, including angiogenesis and metastasis.
• Osteosarcoma (OS) is a common primary bone malignancy, yet the specific role of ITGAV in OS requires further investigation.
• Aberrant microRNA expression is a hallmark of various cancers, suggesting their potential as biomarkers and therapeutic targets.

Purpose of the Study:

• To investigate the role of miR-548c-3p in osteosarcoma.
• To determine the relationship between miR-548c-3p and integrin αv (ITGAV) in OS.
• To evaluate the therapeutic potential of targeting the miR-548c-3p/ITGAV axis in OS.

Main Methods:

• Collected OS tissues and adjacent normal tissues for expression analysis.
• Utilized luciferase reporter assays to confirm direct targeting of ITGAV by miR-548c-3p.
• Performed gain-of-function (overexpression) and loss-of-function (knockdown) studies for miR-548c-3p and ITGAV, respectively.
• Assessed cell vitality, apoptosis, cell cycle progression, and colony formation assays.

Main Results:

• miR-548c-3p expression was significantly downregulated in OS tissues and cell lines compared to controls.
• miR-548c-3p directly targets the 3'-untranslated region of ITGAV, inhibiting its mRNA and protein levels.
• Overexpression of miR-548c-3p or knockdown of ITGAV suppressed OS cell vitality, induced apoptosis, promoted G2/M cell cycle arrest, and inhibited colony formation.

Conclusions:

• miR-548c-3p acts as a tumor suppressor in osteosarcoma by negatively regulating ITGAV.
• The miR-548c-3p/ITGAV pathway represents a promising therapeutic target for osteosarcoma treatment.
• This finding aligns with ongoing clinical trials targeting integrin αv.